Immune-mediated polyneuropathy/chronic inflammatory demyelinating polyneuropathy (CIDP): diagnostic, prognostic, and treatment-response markers
- Conditions
- G61Inflammatory polyneuropathy
- Registration Number
- DRKS00032455
- Lead Sponsor
- Charité - Universitätsmedizin Berlin
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 320
• Patients with CIDP or CIDP variants (DADS, MADSAM, purely sensory/purely motor, focal courses) or other immune-mediated polyneuropathies [multifocal motor neuropathy, polyneuropathy of the rheumatic type or chronic inflammatory bowel diseases, chronic inflammatory axonal polyneuropathy (CIAP) , autoimmune (para)nodopathies Guillian Barré Syndrome, polyneuropathies in the context of monoclonal gammopathies of unclear significance, anti-MAG neuropathies]
• Age- and sex-matched subjects with polyneuropathy of other origin (hereditary, diabetic/toxic origin)
• control patients of the same age and gender with central demyelinating disease (multiple sclerosis)
• Age- and sex-matched healthy subjects with no other underlying autoimmune-mediated disease or comorbidities
• Ability to consent and written informed consent
none
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method activity of dealy life score
- Secondary Outcome Measures
Name Time Method - Analysis of antibodies, proteins, RNA and DNA etc. in bio samples<br>- Questionnaires on severity perception, quality of life, depression, fatigue and cognition<br>- Electrophysiological investigations